The Effects of Cerebellar rTMS on Brain Activity

Sponsor
University of Manchester (Other)
Overall Status
Suspended
CT.gov ID
NCT05736380
Collaborator
(none)
8
1
2
16
0.5

Study Details

Study Description

Brief Summary

Swallowing function is controlled by two swallowing centres (one on each half of the brain). There is a dominant and non-dominant swallowing centre. Damage to any part of the brain can lead to swallowing problems, for example in strokes. Recovery of the ability to swallow is associated with increased activity (compensation) over the undamaged centre. The cerebellum is an area of the brain involved in the control and modulation of muscle movements. It is found at the back of the skull. Anatomical evidence exists, showing cerebellar outputs projecting to several cortical areas, including the primary motor cortex (M1). Moreover, brain imaging studies have shown activation of the cerebellum during swallowing using positron emission tomography (PET) and magnetic resonance imaging (MRI).

Over the past few years studies have tried to improve swallowing function using techniques to stimulate regions of the brain and encourage compensation. Repetitive transcranial magnetic stimulation (rTMS) is a technique which can temporarily increase or suppress activity over regions of the brain. No imaging studies have been conducted which have looked at how the brain is affected by cerebellar rTMS.

The investigators hypothesise that cerebellar rTMS will cause increased activity in swallowing associated areas in the brain, including the cortex and brainstem

Condition or Disease Intervention/Treatment Phase
  • Device: Cerebellar rTMS
  • Device: Sham cerebellar rTMS
N/A

Detailed Description

Experiment The optimal motor stimulation sites for pharyngeal and thenar cortical areas and the cerebellum will be identified and marked using single pulse TMS with a coil. Anatomical landmarks will be used to help guide neuronavigation. The vertex (top) of the head will be identified with a tape measure as will the inion (the most prominent part at the back of the skull). Studies have demonstrated that pharyngeal (throat) and thenar (thumb) cortical areas are found in front and to the side of the vertex while both halves of the cerebellum lie below and to the side of the inion. The thenar resting motor threshold over the dominant pharyngeal hemisphere is required for calculation of cerebellar rTMS intensity.

Participants will then be randomly allocated to either real right sided cerebellar rTMS or sham (pretend) cerebellar rTMS on each visit. Each participant will undergo both procedures (real and sham) over the course of their involvement with the study. Real cerebellar rTMS will be delivered by holding the figure of eight coil flat against the head. It will be administered at 90% of thenar resting motor threshold at a frequency of 10 Hertz. Sham cerebellar rTMS will be delivered by holding the coil perpendicular to the scalp with only the edge of the coils making contact with the head. This technique has been used in previous studies and will ensure that no stimulation is delivered to the cerebellum.

After real or sham cerebellar rTMS, participants will have functional magnetic resonance imaging (fMRI) scans of their brains. During the scan participants will be asked to swallow water through a plastic tube. This will activate their brain swallowing centres. Each participant will be asked to complete five swallowing cycles. Each cycle will involve swallowing 10 times with a one second gap between swallows. Cycles will be separated by a 10 second period of rest.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
8 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Over the course of two visits to the laboratory, each participant will undergo either real or sham cerebellar rTMS. Afterwards they will have functional magnetic resonance imaging of their brains.Over the course of two visits to the laboratory, each participant will undergo either real or sham cerebellar rTMS. Afterwards they will have functional magnetic resonance imaging of their brains.
Masking:
Single (Participant)
Masking Description:
Over the course of two visits to the laboratory, each participant will be randomised to either real or sham cerebellar rTMS. Each participant will undergo both procedures.
Primary Purpose:
Basic Science
Official Title:
The Effects of Cerebellar rTMS on Brain Activity
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Unilateral cerebellar rTMS

Device: Cerebellar rTMS
250 pulses at 10 Hertz over the cerebellum

Sham Comparator: Sham cerebellar rTMS

Device: Sham cerebellar rTMS
Sham cerebellar rTMS

Outcome Measures

Primary Outcome Measures

  1. Differential blood flood (fMRI) [15 minutes post cerebellar rTMS]

    Differential blood flow in brain regions post cerebellar rTMS (compared to sham)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Healthy adults above 18 years of age

Exclusion Criteria:
  1. Epilepsy

  2. Cardiac pacemaker

  3. Previous brain surgery

  4. Previous swallowing problems

  5. The use of medication which acts on the central nervous system

  6. Any implanted metal in the head

Contacts and Locations

Locations

Site City State Country Postal Code
1 Upper G.I laboratory, Salford Royal Hospital Manchester Greater Manchester United Kingdom M6 8HD

Sponsors and Collaborators

  • University of Manchester

Investigators

  • Principal Investigator: Shaheen Hamdy, University of Manchester

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prof Shaheen Hamdy PhD FRCP, Professor, University of Manchester
ClinicalTrials.gov Identifier:
NCT05736380
Other Study ID Numbers:
  • IRAS 256390
First Posted:
Feb 21, 2023
Last Update Posted:
Feb 21, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Feb 21, 2023